Recent studies have shown effective use of intravascular filtration devices to remove chemotherapy drugs; however, accurate quantification of the drug’s distribution on the device, within the targeted organ, and systemically, is necessary. We synthesized 18F analog of doxorubicin, fluorobenzylamide doxorubicin ([18F]FB-Dox), which was administered via an intra-arterial catheter, without a filter, and imaged under PET/MRI in vivo. [18F]FB-Dox showed a measurable decrease in the liver, and an increase in the bladder, kidney, and gall bladder over a 90-minute period after injection. This demonstrates a viable way to assess and track the baseline biodistribution of an intra-arterial chemotherapy procedure.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords